- 180 Life Sciences Granted an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
- 180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
- 180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
- 180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
- 180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
- 180 Life Sciences Announces Review of Strategic Alternatives
- 180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
- 180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
- 180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
- 180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA
More ▼
Key statistics
On Friday, 180 Life Sciences Corp (ATNF:NAQ) closed at 2.30, 75.57% above the 52 week low of 1.31 set on May 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.25 |
---|---|
High | 2.41 |
Low | 2.21 |
Bid | 2.25 |
Offer | 2.64 |
Previous close | 2.30 |
Average volume | 121.70k |
---|---|
Shares outstanding | 941.59k |
Free float | 913.05k |
P/E (TTM) | -- |
Market cap | 2.17m USD |
EPS (TTM) | -41.54 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 21:00 BST.
More ▼